Literature DB >> 17011824

Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.

Theo Louis Peeters1.   

Abstract

Ghrelin was first discovered as a peptide involved in growth hormone release, but has now emerged as a new player in the regulation of gastrointestinal function. Ghrelin is structurally and functionally related to motilin. Like motilin, it induces a specific motor pattern in the fasted state and acts postprandially to accelerate gastric emptying. There is no apparent cross-reactivity with motilin at the receptor level. Ghrelin agonists have the same potential as motilin agonists, and applications in post-operative ileus and gastroparesis have already been explored. Although promising, there is still the need to avoid side effects and the problems encountered with motilides. This will require drugs with an appropriate pharmacokinetic profile. In addition, the dosage regimen and target population should be carefully taken into consideration when planning clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011824     DOI: 10.1016/j.coph.2006.08.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  10 in total

1.  Intragastric injection of botulinum toxin for the treatment of obesity. Where are we?

Authors:  Diego Garcia-Compean; Hector Maldonado Garza
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

2.  Vagotomy upregulates expression of the N-methyl-D-aspartate receptor NR2D subunit in the stomach.

Authors:  Kanako Watanabe; Takeshi Kanno; Tadayuki Oshima; Hiroto Miwa; Chikara Tashiro; Tomoyuki Nishizaki
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

Review 3.  Endoscopic treatment of obesity.

Authors:  Agnieszka Swidnicka-Siergiejko; Eugeniusz Wróblewski; Dabrowski Andrzej
Journal:  Can J Gastroenterol       Date:  2011-11       Impact factor: 3.522

4.  Ghrelin in female and male reproduction.

Authors:  Joëlle Dupont; Virginie Maillard; Stéphanie Coyral-Castel; Christelle Ramé; Pascal Froment
Journal:  Int J Pept       Date:  2010-03-14

Review 5.  Actions and therapeutic pathways of ghrelin for gastrointestinal disorders.

Authors:  Michael Camilleri; Athanasios Papathanasopoulos; Suwebatu T Odunsi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06       Impact factor: 46.802

Review 6.  Advances in the Endoscopic Management of Obesity.

Authors:  Jason Behary; Vivek Kumbhari
Journal:  Gastroenterol Res Pract       Date:  2015-05-28       Impact factor: 2.260

7.  Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists.

Authors:  G J Sanger; Y Wang; A Hobson; J Broad
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

Authors:  Beverley Greenwood-Van Meerveld; Karl Tyler; Ehsan Mohammadi; Claudio Pietra
Journal:  J Exp Pharmacol       Date:  2012-10-19

Review 9.  Botulinum Toxin A for Controlling Obesity.

Authors:  Raffaela Pero; Lorena Coretti; Francesca Lembo
Journal:  Toxins (Basel)       Date:  2016-09-26       Impact factor: 4.546

10.  Can gastric botulinum toxin A injection be used as minimally invasive procedure in the short-term treatment of obesity?

Authors:  Kamil Özdil; A K Çağatay; Süleyman Sayar; Hüseyin Aykut; Ebru Tarıkçı Kılıç
Journal:  J Minim Access Surg       Date:  2022 Apr-Jun       Impact factor: 1.407

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.